Drug profile · INN
bicalutamide
APO-BICALUTAMIDE
bicalutamide (APO-BICALUTAMIDE) is a androgen receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — bicalutamide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 8
- Data quality
- 0.89
Quick answer
bicalutamide (APO-BICALUTAMIDE) is a androgen receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Androgen Receptor antagonist
Primary target: Androgen receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bicalutamide?
bicalutamide (APO-BICALUTAMIDE) is a androgen receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bicalutamide?
APO-BICALUTAMIDE is a marketed brand name for bicalutamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bicalutamide?
bicalutamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.